相关实验视频
Updated: Jun 9, 2025

Intracranial Pharmacotherapy and Pain Assays in Rodents
Published on: April 9, 2019
对于通常处方的品牌神经病药物,成本仍在上升
Amanda V Gusovsky1, Chun Chieh Lin1, Kevin Kerber1
1From The Center for the Advancement of Team Science, Analytics, and Systems Thinking in Health Services and Implementation Science Research (CATALYST) (A.V.G.), College of Medicine, and Department of Neurology (C.C.L., K.K., J.F.B.), Division of Health Services Research, Wexner Medical Center, The Ohio State University, Columbus; Department of Epidemiology and Biostatistics (E.L.R.), Michigan State University, East Lansing; and Department of Neurology (B.C.C.), University of Michigan, Ann Arbor.
神经系统疾病的药物费用各不相同. 仿制药降低了自费费用,除了多发性硬化症 (MS) 之外,那里的成本正在上升,需要政策干预.
科学领域:
- 神经学 神经学
- 药物经济学 药物经济学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 药物成本显著影响患者遵守药物规则和医疗保健系统.
- 了解常见的神经疾病的药物成本趋势对于有效的患者管理和政策制定至关重要.
研究的目的:
- 分析2012年至2021年期间五种流行神经病的药物成本趋势,包括自付药费 (OOP) 和总成本.
- 为了比较与品牌与仿制药相关的成本,并评估仿制药引入对患者费用的影响.
主要方法:
- 利用商业索赔数据库识别和跟踪被诊断患有,多发性硬化症 (MS),帕金森病 (PD),外围神经病变 (PN) 和痴呆症/阿尔茨海默病的患者的药物成本.
- 从2012年到2021年,量化年度OOP和药物总开支的截面.
主要成果:
- 多发性硬化药物的自费费用显示,每年平均增加了217%的大幅度增长.
- 与仿制药相比,症药物在品牌版本的OOP成本较高.
- 随着它们的通用可用性,观察到duloxetine,pregabalin,rasagiline,rivastigmine和memantine的OOP成本显著降低 (48%-80%).
结论:
- 在大多数研究的神经疾病中,选择通用药物是一种有效的策略,可以降低OOP成本.
- 多发性硬化症 (MS) 药物是一个例外,成本不断增加,突显了有针对性的政策干预的需要.
- 政策解决方案,如成本上限,被推用于解决在特定神经疾病中不断升级的药物开支.
相关概念视频
Drugs Affecting Neurotransmitter Synthesis
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Drug Therapy
Antianxiety Medications
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drugs Affecting Neurotransmitter Release or Uptake
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

